High Vitamin D Levels Linked to Fewer Cognitive Problems in Study
People with Parkinson’s disease who have higher levels of vitamin D in their blood are less likely to experience…
Articles by Marisa Wexler, MS
UB-312 Vaccine Well Tolerated by Healthy Adults in Ongoing Trial
UB-312, an experimental vaccine targeting aggregated and toxic forms of alpha-synuclein to treat Parkinson’s disease, was generally well tolerated at…
‘Forced’ Cycling May Best Help Those With More Severe Motor Symptoms
Parkinson’s patients who have more severe motor symptoms are more likely to derive a benefit from high-cadence dynamic cycling,…
Spine Implants May Help Clear Up Orthostatic Hypotension
Electrical implants in the spine can clear up feelings of lightheadedness upon standing — the result of a condition called…
Oral GT-02287 Shows Potential to Support Nerve Cell Health
Treatment with GT-02287, an experimental oral therapy for Parkinson’s disease, corrected numerous damaging abnormalities associated with Parkinson’s in cell models,…
Isolation Due to Pandemic Affected Patients’ Mental Health, Cognition
A loss of social support due to the COVID-19 pandemic is tied to poorer mental health and more severe cognitive…
Signs of Aging in the Eyes Tied to Higher Parkinson’s Risk
Markers of age in the retina — the layer of tissue at the back of the eyeball chiefly responsible for…
#AAN2022 – ND0612 Shows Good Safety Profile After 4+ Years
ND0612, an investigational formulation of carbidopa/levodopa delivered continuously via a subcutaneous pump, was generally well-tolerated for more than…
‘Clueless’ Gene May Lead to New Parkinson’s Treatments: Fly Model
Over-expressing a fly gene called clueless (clu) can lessen mitochondrial defects in fruit fly models of Parkinson’s disease, a new…
#AAN2022 – IPX-203 Gives 1.5+ Hours More ‘Good On’ Time Per Dose
Treatment with oral IPX-203, Amneal Pharmaceuticals’ investigational extended-release carbidopa-levodopa (CD/LD) formulation, reduced “off” time by about 1.5 hours a…